Reference, calibration and referral laboratories – a look at current European provisions and beyondShow others and affiliations
2025 (English)In: Clinical Chemistry and Laboratory Medicine, ISSN 1434-6621, E-ISSN 1437-4331, Vol. 63, no 4, p. 656-Article, review/survey (Refereed) Published
Abstract [en]
European Union (EU) regulations on in vitro diagnostics (IVD) and on serious cross-border threats to health provide for the establishment of European Reference Laboratories (EURLs) and their harmonization and cooperation with National Reference Laboratories (NRLs). While the EURLs under the IVD Regulation will be operational by 1 October 2024, the EURLs under the Regulation on serious cross-border threats to health will be operational by January 2025. Although NRLs may have been operating for a long time on the basis of national legislation, they should now cooperate with each other and with EURLs in a network of centers of excellence for the authorization and post-market surveillance of IVDs and for the epidemiological surveillance and control of communicable diseases. The term “reference laboratory” has long been used colloquially to refer to many kinds of laboratories, regardless of their tasks, competencies, responsibilities and designation. A literature search and analysis confirmed this by showing that a considerable proportion of scientific publications in 2024 use the term “reference laboratory” inappropriately. In order to clarify the roles and functioning of EURLs and NRLs, we have evaluated the relevant current EU provisions and compared the findings with those of reference laboratories designated by other organizations, calibration (reference) laboratories and referral laboratories, which are simply referred to as “reference laboratories”. With the forthcoming implementation of the EU regulations, at least the goals of providing safe and high-quality IVDs and adequate public health surveillance for communicable diseases appear to be achievable.
Place, publisher, year, edition, pages
Walter de Gruyter GmbH , 2025. Vol. 63, no 4, p. 656-
Keywords [en]
authorization; calibration; communicable disease; diagnosis; epidemiological monitoring; epidemiological surveillance; European Union; human; patient referral; postmarketing surveillance; public health surveillance; review
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:ri:diva-76164DOI: 10.1515/cclm-2024-1066Scopus ID: 2-s2.0-85207632424OAI: oai:DiVA.org:ri-76164DiVA, id: diva2:1914544
2024-11-192024-11-192025-09-26Bibliographically approved